Search PubMedSearch

PubMed · 1234731

[General methods and specifications].

Abstract

The reasons are explained why general methods are described in pharmacopeias. With the help of examples taken from European Pharmacopeias, the United States Pharmacopeia, and the International Pharmacopeia, the author reports the general chemical and physical methods that were used in compiling these pharmacopeias. The description of these general methods, and particularly of the instruments, goes often beyond the actual bounds of a pharmacopeia and may fulfill a didactic function. The methods used in the various pharmacopeias, especially the chemical ones, are here compared and subjected to the author's critical analysis. The author explains also that technical progress in the analytical field should not be hampered by the rigidity of the pharmacopeia's rules; this can be easily avoided by resorting to alternate methods.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L Anker. 1975. [General methods and specifications].. https://pubmed.ncbi.nlm.nih.gov/1234731/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Formulation of triamcinolone acetonide pellets suitable for coating and colon targeting.

Spherical pellets containing 5% of triamcinolone acetonide (TA) were formed by extrusion/spheronization following formulation with microcrystalline cellulose (MCC) and/or a hydrophilic excipient (lactose, sodium carboxymethylcellulose or beta-cyclodextrin, beta-CD). Their suitability for coating, with a view to colonic drug delivery, was assessed in terms of their size, sphericity and dissolution test response. Best results were afforded by 5:90:5 MCC-beta-CD-TA pellets obtained by complexation of TA with beta-CD prior to addition of MCC, extrusion and spheronization.

Chemistry, Pharmaceutical

Typical variability in drug dissolution testing: study with USP and FDA calibrator tablets and a marketed drug (glibenclamide) product.

To evaluate variability in drug dissolution testing 28 laboratories analyzed USP calibrators, US FDA prednisone tablets and a marketed glibenclamide tablet product. The experiments were conducted using paddle and basket methods at 50 (calibrators) and 75 (glibenclamide) rpm. The media employed were deaerated by equilibrating at 37 degrees C for 24 h and by the USP recommended method. The 95% CI values for percent drug release for the USP calibrator tablets were similar to the reported tolerances for the USP Acceptance Ranges; however, individual results from 15 of 28 laboratories suggest that the apparatus would not comply with the USP Apparatus Suitability Criteria. For FDA prednisone calibrator tablets, percent drug release using equilibrated medium was different (P=0.003) than by the USP recommended method. For the glibenclamide tablet results, a CV of 14-37% was observed, depending upon the sampling time and the type of apparatus employed. The results indicate that failure to meet the USP Dissolution Apparatus Suitability Test may not truly mean that the apparatus is 'out of compliance'. Due to the high variability in dissolution testing, in many cases the impact of formulation or manufacturing changes on drug release characteristics may not be observed, in particular with multi-point profiles.

Chemistry, Pharmaceutical

Structure-based and combinatorial search for new RNA-binding drugs.

The discovery by structure-based and combinatorial methods of new RNA-binding drugs presents great opportunities for pharmacological development against drug-resistant bacterial and viral pathogens. A handful of recent RNA structures and more numerous studies of the interaction of combinatorial libraries and oligomeric RNA-binding compounds are providing the foundation for effective RNA-targeted drug discovery programs.

Chemistry, Pharmaceutical